Paper5823930
The synthesis of mouse hemoglobin beta-chains in a rabbit reticulocyte cell-free system programmed with mouse reticulocyte 9S RNA.
Lockard RE and 1 other. Biochem Biophys Res Commun, 1969. Cited by 253 papers, by iCite.
Cite this record
ConductScience Library. The synthesis of mouse hemoglobin beta-chains in a rabbit reticulocyte cell-free system programmed with mouse reticulocyte 9S RNA. Papers, record 5823930. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/5823930
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The synthesis of mouse hemoglobin beta-chains in a rabbit reticulocyte cell-free system programmed with mouse reticulocyte 9S RNA.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hemoglobins | Major topic |
| Peptide Biosynthesis | Major topic |
| RNA, Messenger | Major topic |
| Reticulocytes | Major topic |
| Animals | |
| Carbon Isotopes | |
| Cell-Free System | |
| Centrifugation, Density Gradient | |
| Chromatography, Ion Exchange | |
| Globins | |
| Leucine | |
| Mice | |
| Peptides | |
| Rabbits | |
| Ribosomes | |
| Tritium |
Source PubMed
Cited by60
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 253 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42728430 | Structural evolution of ionizable lipids for nucleic acid delivery. | Nat Rev Chem | 2026 | https://conductscience.org/library/papers/42728430 | PubMed |
| 41981145 | mRNA medicine for cardiovascular disease. | Nat Cardiovasc Res | 2026 | https://conductscience.org/library/papers/41981145 | PubMed |
| 40881859 | Unraveling the potential: mRNA therapeutics in oncology. | Front Oncol | 2025 | https://conductscience.org/library/papers/40881859 | PubMed |
| 40243757 | In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40243757 | PubMed |
| 40195623 | Engineering Lipid Nanoparticles for mRNA Immunotherapy. | Wiley Interdiscip Rev Nanomed Nanobiotechnol | 2025 | https://conductscience.org/library/papers/40195623 | PubMed |
| 39543114 | Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/39543114 | PubMed |
| 39179112 | Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies. | J Control Release | 2024 | https://conductscience.org/library/papers/39179112 | PubMed |
| 39171210 | Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology. | Precis Clin Med | 2024 | https://conductscience.org/library/papers/39171210 | PubMed |
| 39027251 | Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders. | Acta Pharm Sin B | 2024 | https://conductscience.org/library/papers/39027251 | PubMed |
| 37834268 | The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37834268 | PubMed |
| 37794448 | Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy. | J Transl Med | 2023 | https://conductscience.org/library/papers/37794448 | PubMed |
| 37726283 | mRNA vaccines in disease prevention and treatment. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/37726283 | PubMed |
| 37656402 | mRNA-Based Nanomedicine: A New Strategy for Treating Infectious Diseases and Beyond. | Eur J Drug Metab Pharmacokinet | 2023 | https://conductscience.org/library/papers/37656402 | PubMed |
| 37470024 | Messenger RNA-Based Therapeutics and Vaccines: What's beyond COVID-19? | ACS Pharmacol Transl Sci | 2023 | https://conductscience.org/library/papers/37470024 | PubMed |
| 36932293 | mRNA therapy at the convergence of genetics and nanomedicine. | Nat Nanotechnol | 2023 | https://conductscience.org/library/papers/36932293 | PubMed |
| 36678793 | mRNA in the Context of Protein Replacement Therapy. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/36678793 | PubMed |
| 36471724 | Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics. | Bioact Mater | 2023 | https://conductscience.org/library/papers/36471724 | PubMed |
| 36224645 | Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. | Mil Med Res | 2022 | https://conductscience.org/library/papers/36224645 | PubMed |
| 35424872 | A brief review of mRNA therapeutics and delivery for bone tissue engineering. | RSC Adv | 2022 | https://conductscience.org/library/papers/35424872 | PubMed |
| 35322018 | Advances in COVID-19 mRNA vaccine development. | Signal Transduct Target Ther | 2022 | https://conductscience.org/library/papers/35322018 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/5823930
GET https://conductscience.org/api/papers/v1/5823930/cited_by?page=2